Plasma Protein Therapeutics Market is Expected to Reach US$31.84 Bn by the end of 2024

Aug 28, 2017

The use of plasma protein therapeutics has significantly increased in medical applications. This, coupled with the rising aging population, its medicinal use in novel indications, and the advent of new plasma-derived therapies, has been propelling the market for plasma protein therapeutics. Transparency Market Research (TMR) projects the market to continue exhibiting robust growth worldwide between 2016 and 2024.

Recent advancements introduced in plasma protein therapeutics aimed at improving the quality of patient care have been pivotal in fuelling their demand. These advancements have also proven crucial in guaranteeing donor’s safety. The increasing demand for immunoglobulin (IG) and the increasing use of protein therapeutics will thus augment demand for plasma protein therapeutics. TMR expects, the global market for the same to rise at a CAGR of 7.0% between 2016 and 2024. The market stood at US$18.5 bn in 2015 and is expected to reach US$31.84 bn by the end of 2024. Despite exhibiting growth at a positive rate, stringent regulations and lack of proper reimbursement policies could hamper the market’s trajectory.

Obtain Report Details @
http://www.transparencymarketresearch.com/plasma-protein-therapeutics-market.html

North America, trailed by Europe, Exhibits Most Lucrative Prospects for Market

Regionally, North America, Asia Pacific, Europe, Latin America, and Rest of the World constitute the most lucrative markets for plasma protein therapeutics. Among these regions, North America held the dominant share in the global market in 2015, trailed by Europe. New indications, the increasing geriatric population, and investments in novel researches are boosting prospects for the market in North America. As per TMR, the North America plasma protein therapeutics market is expected to reach US$13.8 bn by the end of 2024 from a valuation of US$7.5 bn in 2015. If the figures hold true, the regional market will exhibit a CAGR of 7.9% during the forecast period.

In Europe, demand for protein therapeutics is increasing consequent to the rise in the number of clinical indications for immunoglobulin. Since immunoglobulin finds application across hematology, neurology, dermatology, nephrology, immunology, ophthalmology, rheumatology, and others, demand for protein therapeutics in Europe is expected to remain high.

During the forecast period, TMR projects Asia Pacific to emerge as the most lucrative market for plasma protein therapeutics. The rising demand for albumin and immunoglobulin in Asia Pacific is bolstering prospects for expansion of the market in the region. Furthermore, the region is also known to import albumin and immunoglobulin from North America and Europe. China as per TMR, imports nearly half of its albumin supply in order to bridge the demand and supply gap. The albumin segment is thus expected to register the fastest growth in Asia Pacific. In Latin America, however, the plasma protein therapeutics market is restrained by low rate of diagnosis and treatment and high pricing.

Growth to be Facilitated by Rising Incidence of Immunodeficiency Disorders

Plasma protein therapeutics is increasingly used in the treatment of primary immunodeficiency disorder (PID). The PID segment is likely to exhibit a CAGR of 7.6% between 2015 and 2024. The PID treatment segment is poised to gain considerably from the increasing investment immunoglobulin. Furthermore, with the increasing incidence of secondary immunodeficiency disorders, applications of plasma protein therapeutics is likely to increase across the treatment of prolonged illnesses. The most common secondary immunodeficiency disorders include diabetes, myeloma, HIV infection, and under-nutrition. Despite being a rare disorder, treatment of hereditary angioedema (HAE) has become possible due to the growing awareness regarding the disease worldwide. This is expected to boost the demand for plasma protein therapeutics significantly.

Some of the leading players operating in the global plasma protein therapeutics market include

Baxter International, Biotest, CSL Behring, Grifols, S.A., Kedrion, Octapharma USA, Inc., Shire plc, and China Biologics.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=10424

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com
Browse market research blog:
https://tmrresearch.blogspot.com/

Name: Rohit Bhisey
Organization: Transparency Market Research
Website: http://www.transparencymarketresearch.com

More News

Xi Jinping urges trust-based partnership with Australia in Shenzhen bilateral talks
Nov 20, 2026
Xi Jinping urges trust-based partnership with Australia in Shenzhen bilateral talks

China and Australia should be “partners that trust each other”, President Xi Jinping told Australian Prime Minister Anthony Albanese in Shenzhen on Friday. Xi struck an upbeat tone on Beijing’s relationship with Canberra, describing it as “developing steadily” now, in the meeting after the Asia-Pacific Economic Cooperation leaders’ summit in the southern Chinese city. “China and Australia have neither historical grievances nor fundamental conflicts of interest, and should be partners who trust...

Supreme Court declines separate listing of recall plea in CEC appointment case
Nov 20, 2026
Supreme Court declines separate listing of recall plea in CEC appointment case

The Supreme Court declined a request to separately list a recall plea related to the split verdict. The plea questions the 2023 law that governs the appointment of election commissioners. Chief Justice Surya Kant stated the recall application could be considered by the existing five-judge Constitution bench. Justice Sharma's impending retirement and conflict of interest were raised during the proceedings.

Gujarat bans caste-identifying stickers, signs and words on private vehicles
Nov 20, 2026
Gujarat bans caste-identifying stickers, signs and words on private vehicles

The Gujarat government has introduced explicit restrictions on caste-related displays on private vehicles through an amendment to its motor vehicle rules

Cyclone Akvan triggers rain in south Bengal, IMD forecasts downpours till Saturday
Nov 20, 2026
Cyclone Akvan triggers rain in south Bengal, IMD forecasts downpours till Saturday

The India Meteorological Department (IMD) forecast very heavy rain over the coastal districts of South 24 Parganas and Purba Medinipur till Saturday

India, Japan deepen defence, tech, and economic security ties as EAM Jaishankar concludes Tokyo visit
Nov 20, 2026
India, Japan deepen defence, tech, and economic security ties as EAM Jaishankar concludes Tokyo visit

During the visit, Jaishankar participated in the fourth India-Japan Foreign and Defence Ministerial Dialogue (2+2) alongside Defence Minister Rajnath Singh and their Japanese counterparts, Foreign Minister Toshimitsu Motegi and Defence Minister Shinjiro Koizumi.

'Worrying Isn't Going To Improve....': Viswanathan Anand's Guru Mantra To D Gukesh Ahead Of World Championship
Nov 20, 2026
'Worrying Isn't Going To Improve....': Viswanathan Anand's Guru Mantra To D Gukesh Ahead Of World Championship

Viswanathan Anand has advised D Gukesh to relax and enjoy his chess ahead of his world title defence against Javokhir Sindarov in Geneva.

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

Daily World Feed

Get yourself immersed in engaging topics right here. Daily World Feed is a multi-platform media, providing you latest breaking news straight from the industry.

Sign Up